Inhibition of cytochrome P450 by nefazodone in vitro: Studies of dextromethorphan O- and N-demethylation

British Journal of Clinical Pharmacology

Volumn 41, Issue 4, 1996, Pages 339-343

  Schmider, Jürgen ^a   Greenblatt, David J ^a   Von Moltke, Lisa L ^a   Harmatz, Jerold S ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2D6 cytochrome P450; CYP3A3 4; Dextromethorphan; Human liver microsomes; In vitro; Nefazodone

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; BMS 183562 01; BMS 183695 01; BMY 33604; CYTOCHROME P450; DEXTROMETHORPHAN; DRUG METABOLITE; HYDROXYNEFAZODONE; NEFAZODONE; UNCLASSIFIED DRUG;

ARTICLE; DEMETHYLATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER MICROSOME; PHENOTYPE; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DEXTRORPHAN; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDOREDUCTASES, O-DEMETHYLATING; TRIAZOLES;

EID: 0029979348     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.30512.x     Document Type: Article

References (22)

1. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiat 1994; 55: 234-241.
2. Rickels K, Schweizer E, Clary C, Fox I, Weise C. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiat 1994; 164: 802-805.
3. Anton SF, Robinson DS, Roberts DL, Kensler TT, English PA, Archibald DG. Long-term treatment of depression with nefazodone. Psychopharmacol Bull 1994; 30: 165-169.
4. 14C] nefazodone in the dog. Drug Metab Dispos 1993; 21: 502-507.
5. Shukla UA, Kaul S, Marathe PH, Pittman KA, Barbhaiya RH. Pharmacokinetics of nefazodone following multiple escalating oral doses in the dog. Eur J Drug Metab Pharmacokin 1992; 17: 309-318.
6. Shukla UA, Marathe PH, Labudde JA, Pittman KA, Barbhaiya RH. Pharmacokinetics of nefazodone in the dog following single oral administration. Eur J Drug Metab Pharmacokin 1992; 17: 301-308.
7. Ferry N, Bernard N, Cuisinaud G, Rougier P, Trepo C, Sassard J. Influence of hepatic impairment on the pharmacokinetics of nefazodone and two of its metabolites after single and multiple oral doses. Fundam Clin Pharmacol 1994; 8: 463-473.
8. Franc JE, Duncan GF, Farmen RH, Pittman KA. High-performance liquid chromatographic method for the determination of nefazodone and its metabolites in human plasma using laboratory robotics. J Chromatogr 1991; 570: 129-138.
9. Walsh AE, Cowen PJ. Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment. J Clin Psychopharmacol 1994; 14: 268-273.
10. van Laar MW, van Willigenburg APP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J Clin Psychopharmacol 1995; 15: 30-40.
11. Mayol RF, Cole CA, Luke GM, Colson KL, Kerns EH. Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab Dispos 1994; 22: 304-311.
12. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T. CYP2D6-and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 1993; 3: 197-204.
13. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 48: 173-182.
14. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993; 47: 268-276.
15. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994; 268: 1278-1283.
16. Norby J, Rubenstein S, Tuerke T, Farmer S, Forood R, Bennington J. SigmaPlot, v. 4.13. Jandel Corporation 1991.
17. Scavone MJ, Friedman H, Greenblatt DJ, Shader RI. Effect of age, body composition, and lipid solubility on benzodiazepine tissue distribution in rats. Arzneimittel-Forschung 1987; 37: 2-6.
18. Greene DS, Dockens RC, Salazar DE, Barbhaiya RH. Coadministration of nefazodone (NEF) and benzodiazepines I: Pharmacokinetic assessment. Clin Pharmacol Ther 1994; 55: 141.
19. Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS. Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995; 15: 320-326.
20. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
21. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31.
22. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15: 125-131.